• LMTK2 Modulates Inflammation in LPS-Stimulated Microglia via

  2026-06-18

  Rui et al. reveal that Lemur tyrosine kinase 2 (LMTK2) regulates neuroinflammatory responses in LPS-activated BV2 microglia through modulation of the Nrf2/HO-1/NQO1 pathway. Their work clarifies LMTK2’s potential as a molecular target in neuroinflammation, with implications for developing new interventions in neurodegenerative disease models.

• D-N-Acetylgalactosamine: Technical Use in Brain Glycoprotein

  2026-06-18

  D-N-Acetylgalactosamine is a high-purity, water-soluble metabolite designed to support precise glycoprotein constituent analysis in neurological workflows, particularly for brain heteropolysaccharides and glycosylation pathway studies. It is not suitable for protocols requiring ethanol solubility or for applications needing long-term storage of prepared solutions, and strict adherence to storage and handling parameters is essential for data reliability.

• Steroid-Induced Lysis of Bacterial Protoplasts: Mechanisms a

  2026-06-17

  Smith and Shay's 1965 study innovatively used bacterial protoplasts to dissect the membrane-targeting actions of synthetic steroids and their antagonists. The findings clarify how direct membrane disruption, rather than cell wall interaction, underlies the antimicrobial effects of these compounds, offering protocols for membrane-based antimicrobial studies.

• Fingolimod (FTY720): Mechanisms, Benchmarks, and MS Applicat

  2026-06-17

  Fingolimod (FTY720) is an orally active sphingosine-1-phosphate receptor modulator used for multiple sclerosis. It inhibits lymphocyte egress and upregulates neuroprotective factors, with well-characterized pharmacokinetics and cytotoxicity profiles. The compound's efficacy and limitations are supported by peer-reviewed studies and APExBIO's validated product documentation.

• Fingolimod (FTY720): Data-Driven Solutions for Cell Assays

  2026-06-16

  This article addresses real laboratory challenges with cell viability and immune modulation assays, providing evidence-based guidance on using Fingolimod (FTY720), SKU A8548. By grounding recommendations in quantitative data and peer-reviewed literature, it demonstrates how APExBIO’s high-purity Fingolimod enables reproducible, cost-effective, and robust workflows for biomedical researchers.

• LG 101506: Precision RXR Modulator for Immunometabolic Resea

  2026-06-16

  LG 101506 empowers researchers to dissect RXR signaling with unmatched specificity, enabling advanced studies in immune checkpoint regulation and metabolic disease modeling. Proven in challenging cellular systems, this RXR modulator from APExBIO delivers consistent performance for both discovery and translational workflows.

• AI-Driven Discovery of Senolytics: Innovation and Implicatio

  2026-06-15

  This article analyzes a recent study that applied machine learning to identify novel senolytic agents, offering a significant advance in the targeted elimination of senescent cells. The approach demonstrates both the efficiency of computational drug screening and its potential to accelerate cancer and aging research.

• BML-277 and the Chk2–cGAS Axis: Advancing DDR Research

  2026-06-15

  Explore how BML-277, a potent Chk2 inhibitor from APExBIO, is enabling a new era of DNA damage response (DDR) research. By integrating recent discoveries around the Chk2–cGAS–TRIM41 pathway, this article offers translational researchers strategic guidance for leveraging BML-277 in radioprotection, genome stability, and cancer biology.

• BML-277: Redefining Chk2 Inhibition for Advanced Genome Stab

  2026-06-14

  Explore how BML-277, a potent Chk2 inhibitor, enables precise DNA damage response research and novel radioprotection strategies for T-cells. This article delivers unmatched scientific depth and practical guidance for leveraging BML-277 in innovative assay designs.

• PEDV Replication Requires Host IMPDH: Insights from Merimepo

  2026-06-13

  This study uncovers how porcine epidemic diarrhea virus (PEDV) exploits host IMPDH-dependent nucleotide biosynthesis to promote its replication. Using both genetic and pharmacological approaches, including Merimepodib (VX-497), the authors demonstrate that targeting IMPDH significantly impairs viral propagation, highlighting a promising host-directed antiviral strategy.

• Melittin (SKU B6628): Optimizing Cell Signaling Assays in Ca

  2026-06-12

  Explore how Melittin (SKU B6628), a potent bioactive peptide, addresses real-world laboratory challenges in signal transduction, apoptosis, and cancer biology workflows. This article employs scenario-based analysis to demonstrate Melittin’s practical advantages for reproducibility, data interpretation, and assay optimization, with evidence-based recommendations for biomedical researchers.

• BML-277: Unlocking Posttranslational Control in Chk2–cGAS Pa

  2026-06-12

  Explore the advanced role of BML-277 as a potent Chk2 inhibitor in dissecting posttranslational regulation within the DNA damage response. This article uniquely focuses on practical assay implications and deeper mechanistic insights for radioprotection and cancer research.

• Intestinal TM6SF2 Controls MASH via Gut–Liver Axis and LPA S

  2026-06-11

  This study uncovers the crucial role of intestinal TM6SF2 in protecting against metabolic dysfunction-associated steatohepatitis (MASH) by maintaining gut barrier integrity and modulating host–microbe and lipid signaling. These findings establish new mechanisms underlying MASH pathogenesis and highlight therapeutic entry points involving the gut–liver axis.

• Elevating Cancer Stem Cell Pathway Research with HyperTrap H

  2026-06-11

  Discover how the HyperTrap Heparin HP Column empowers translational researchers to dissect the CCR7–Notch1 stemness axis in breast cancer with unmatched resolution and reproducibility. Explore mechanistic insights, validated protocols, and strategic guidance for leveraging high-density heparin affinity chromatography in next-generation signaling studies.

• Improving In Vitro Drug Response Evaluation in Cancer Resear

  2026-06-10

  Schwartz's dissertation advances cancer drug evaluation by clarifying the distinct roles of growth inhibition and cell death in in vitro assays. The work provides researchers with critical methodological guidance for interpreting drug responses, supporting more reliable preclinical oncology workflows.

16640 records 1/1110 page Next 12345 下5页 Last page